63.98
price up icon2.11%   +1.3212
 
loading
Bio-Techne Corp stock is currently priced at $63.98, with a 24-hour trading volume of 286.41K. It has seen a +2.11% increased in the last 24 hours and a -6.45% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $62.59 pivot point. If it approaches the $64.11 resistance level, significant changes may occur.
Previous Close:
$62.66
Open:
$62.83
24h Volume:
286.41K
Market Cap:
$10.03B
Revenue:
$1.14B
Net Income/Loss:
$224.16M
P/E Ratio:
42.09
EPS:
1.52
Net Cash Flow:
$225.39M
1W Performance:
+3.00%
1M Performance:
-6.45%
6M Performance:
+4.02%
1Y Performance:
-18.40%
1D Range:
Value
$62.40
$64.10
52W Range:
Value
$51.79
$89.91

Bio-Techne Corp Stock (TECH) Company Profile

Name
Name
Bio-Techne Corp
Name
Phone
612-379-8854
Name
Address
614 McKinley Place NE, Minneapolis, MN
Name
Employee
2,100
Name
Twitter
@biotechne
Name
Next Earnings Date
2024-05-01
Name
Latest SEC Filings
Name
TECH's Discussions on Twitter

Bio-Techne Corp Stock (TECH) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-08-24 Initiated Scotiabank Sector Outperform
Feb-02-24 Downgrade Stifel Buy → Hold
Dec-07-23 Initiated UBS Buy
Aug-28-23 Initiated William Blair Outperform
Jan-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Dec-14-22 Initiated Deutsche Bank Buy
Dec-12-22 Upgrade Citigroup Neutral → Buy
Dec-07-22 Initiated RBC Capital Mkts Sector Perform
Aug-25-22 Initiated Credit Suisse Outperform
Apr-25-22 Downgrade Wells Fargo Equal Weight → Underweight
Sep-15-21 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Mar-08-21 Upgrade Stephens Equal-Weight → Overweight
Feb-23-21 Upgrade Stifel Hold → Buy
Jan-25-21 Reiterated The Benchmark Company Buy
Nov-10-20 Initiated KeyBanc Capital Markets Sector Weight
Sep-30-20 Initiated Atlantic Equities Overweight
Jul-15-20 Downgrade Stephens Overweight → Equal-Weight
May-27-20 Downgrade Stifel Buy → Hold
May-14-20 Initiated The Benchmark Company Buy
Jan-08-20 Resumed Stephens Overweight
Jan-08-20 Initiated Wells Fargo Equal Weight
Jan-07-20 Initiated Citigroup Neutral
Nov-15-19 Initiated Stifel Buy
Jul-02-19 Upgrade Janney Neutral → Buy
Jan-14-19 Upgrade Stephens Equal-Weight → Overweight
Oct-31-18 Downgrade Craig Hallum Buy → Hold
Oct-17-18 Initiated Goldman Neutral
Jun-15-18 Initiated Argus Buy
Jul-13-17 Initiated Wells Fargo Market Perform
Feb-09-17 Initiated Citigroup Buy
Jan-18-17 Initiated Deutsche Bank Buy
Nov-10-16 Resumed Leerink Partners Outperform
Jan-21-15 Reiterated Robert W. Baird Outperform
Sep-20-13 Upgrade Robert W. Baird Neutral → Outperform
View All

Bio-Techne Corp Stock (TECH) Financials Data

Bio-Techne Corp (TECH) Revenue 2024

TECH reported a revenue (TTM) of $1.14 billion for the quarter ending December 31, 2023, a +2.25% rise year-over-year.
loading

Bio-Techne Corp (TECH) Net Income 2024

TECH net income (TTM) was $224.16 million for the quarter ending December 31, 2023, a -14.38% decrease year-over-year.
loading

Bio-Techne Corp (TECH) Cash Flow 2024

TECH recorded a free cash flow (TTM) of $225.39 million for the quarter ending December 31, 2023, a -10.55% decrease year-over-year.
loading

Bio-Techne Corp (TECH) Earnings per Share 2024

TECH earnings per share (TTM) was $1.38 for the quarter ending December 31, 2023, a -14.15% decline year-over-year.
loading

Bio-Techne Corp Stock (TECH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nusse Roeland
Director
Mar 07 '24
Sale
76.98
10,400
800,627
43,097
Hippel James
CFO
Dec 19 '23
Option Exercise
31.26
47,289
1,478,254
104,850
Nusse Roeland
Director
Aug 30 '23
Option Exercise
22.40
32,000
716,800
60,811
Nusse Roeland
Director
Aug 30 '23
Sale
80.32
8,939
717,959
51,872
Kelderman Kim
Pres. Diagnostics & Genom
Aug 24 '23
Option Exercise
47.60
2,100
99,960
21,225
Kummeth Charles R.
Chief Executive Officer
Aug 15 '23
Option Exercise
0.00
17,632
0
1,286,944
Kummeth Charles R.
Chief Executive Officer
Aug 05 '23
Option Exercise
0.00
51,516
0
1,310,282
Hippel James
CFO
Aug 05 '23
Option Exercise
0.00
12,876
0
63,896
Kelderman Kim
Pres. Diagnostics & Genom
Aug 05 '23
Option Exercise
0.00
8,060
0
23,264
Kummeth Charles R.
Chief Executive Officer
Jul 21 '23
Sale
88.36
80,000
7,069,024
1,258,766
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
$81.58
price down icon 0.71%
$153.86
price up icon 3.50%
$28.12
price up icon 2.37%
$145.25
price up icon 1.15%
$87.40
price up icon 0.82%
$375.61
price up icon 2.01%
Cap:     |  Volume (24h):